

Filter: minimal size of groups n = 5

## EQA round: RF2/17 - Diagnostics of Rheumatoid Arthritis and ASLO

Dead line: 22.09.2017

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]						Comparability						
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>

## Set of samples 2

(237) anti-streptolysin O (ASLO) [kIU/L] 142 126 121 96%

----- Samples and groups -----

Sample A2	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
(1) Abbott	318	19	6,1	10	0	CVPG	318	15	24%	241	395	10	
(12) Beckman Coulter	343	42	12	13	0	CVPG	343	29	24%	260	426	13	
(49) BioVendor	516	32	6,2	5	0	CVPG	516	90	24%	392	640	5	
(58) Beckman Coulter (Olympus)	470	19	4,1	33	0	CVPG	470	8,2	24%	357	583	33	
(60) Roche	488	36	7,3	35	0	CVPG	488	15	24%	370	606	35	
(115) BioSystems	445	59	13	9	0	CVPG	445	72	24%	338	552	0	
(149) Siemens (Dade)	479	18	3,7	10	0	CVPG	479	14	24%	364	594	10	
(178) DiaSys	509	24	4,7	5	0	CVPG	509	68	24%	386	632	5	
(179) Siemens (Bayer)	573	26	4,6	15	0	CVPG	573	17	24%	435	711	15	
Other				7	0							0	

1x 40, 1x 46, 1x 116, 1x 166, 3x 177

----- Sample B2 ----- 110 17 16 142 126 124 98%

(1) Abbott	85,8	8,3	9,7	10	0	CVPG	85,8	6,5	24%	65,2	107	10	
(12) Beckman Coulter	77,0	9,9	13	13	0	CVPG	77	6,7	24%	58,5	95,5	13	
(49) BioVendor	124	3,5	2,8	5	0	CVPG	124	9,8	24%	94,2	154	5	
(58) Beckman Coulter (Olympus)	104	6,2	5,9	33	0	CVPG	104	2,6	24%	79	129	33	
(60) Roche	116	5,2	4,5	35	0	CVPG	116	2,2	24%	88,1	144	35	
(115) BioSystems	92,0	27	29	9	0	CVPG	92	33	24%	69,9	115	0	
(149) Siemens (Dade)	124	4,5	3,7	10	0	CVPG	124	3,5	24%	94,2	154	10	
(178) DiaSys	121	3,6	2,9	5	0	CVPG	121	10	24%	91,9	151	5	
(179) Siemens (Bayer)	125	7,7	6,1	15	0	CVPG	125	4,8	24%	95	155	15	
Other				7	0							0	

1x 40, 1x 46, 1x 116, 1x 166, 3x 177

st\_kn\_p

End of report

Printed: 04.10.2017